Background {#s1}
==========

Rheumatoid meningitis (RM) is a rare but potentially aggressive extra-articular manifestation of rheumatoid arthritis (RA) involving both pachy- and leptomeninges ([@B1], [@B2]). It can occur at all disease stages, and manifestations are often non-specific, mimicking a variety of neurological disorders, malignancies, or infections ([@B1]--[@B6]). Brain MRI with patchy leptomeningeal contrast enhancement and cerebrospinal fluid (CSF) rheumatoid factor (RF) are useful to guide, but diagnosis still relies on pathological examination of a meningeal biopsy often showing unspecific inflammation, rheumatic noduli, and in some cases vasculitis ([@B2], [@B7]--[@B11]). Four recent cases have shown presence of CSF anti-cyclic citrullinated peptide (anti- CCP) in patients with RM ([@B12]--[@B15]). Here, we describe a patient with RM with strongly positive anti-CCP, IgM RF, and chemokine (C-X-C motif) ligand 13 (CXCL13) levels in CSF that normalized after treatment suggesting a potential use of these markers in both diagnosis and treatment management of RM. Furthermore, we review 48 cases of RM published in the English literature since 2010 focusing on symptoms, serum and CSF findings, treatment, and outcome.

Case Presentation {#s2}
=================

A 62 year-old woman was admitted after 4 months history of intermittent frontal headache, nausea, and gait and balance disturbances. She had a 3 year history of IgM-RF and anti-CCP positive RA, with a previously episode of pleuritis. Within the last year, she had been treated with Leflunomide, Infliximab, and was currently treated with Methotrexate and Salazopyrine entabs. Neurological examination was normal, except for a mild gait ataxia and her RA was well-controlled with no symptoms of active synovitis at time of admission.

Due to chronic headache a brain MRI was performed. This showed patchy interhemispheric pachy- and leptomenigeal enhancement adjacent to the parietal- and occipital lobes ([Figure 1A](#F1){ref-type="fig"}). Blood tests revealed signs of inflammation with high levels of IgM RF (56 IU/mL), anti-CCP (\>1,600 U/mL), Interleukin-2 receptor (ILR-2--1,065 kU/L) ([Table 1](#T1){ref-type="table"}), c-reactive protein (43 mg/L), and erythrocyte sedimentation rate (106 mm). Remaining systemic antibody examinations were negative (anti-DNA antibody, anti-nuclear antibody (ANA) IgG, anti-neutropil cytoplasmatic antibody (ANCA) IgG, Anti-Ro (SSA)/La (SSB), anti-cardiolipin antibody, phospholipid antibody, and lupus anticoagulant). Immunoglobulin A, G, and M levels were normal.

![T1-weighted brain MRI showing interhemispheric leptomeningeal Gd+ enhancement before **(A)** and after **(B)** treatment with high dose steroids, Methotrexate and Rituximab. On gross inspection meninges appear severely inflamed **(C)** and pathological examination reveals massive meningeal granulomatous inflammation **(D)** with pre-dominant CD138 positive plasma cells **(E)**, but also CD3 positive T cells **(F)**. Massive infiltration with CD68 positive histiocytes with rheumatic granuloma formation was also seen **(G)**.](fneur-10-00666-g0001){#F1}

###### 

Serum and CSF markers before and after treatment.

  **Test/(range)**                                         **Pre-treatment**   **Post-treatment**
  -------------------------------------------------------- ------------------- --------------------
  **Serum**                                                                    
  IgM RF (\<15 IU/mL)                                      56                  18
  Anti-CCP (\<25 U/mL)                                     \>1,600             706
  ILR-2 (158--623 kU/L)                                    1,065               N/A
  **CSF**                                                                      
  Leukocytes (\<5 E6/L)                                    170                 \<5
  Protein (0.40--0.70 g/L)                                 1.16                0.28
  IgG index (\<0,60)                                       1.45                0.45
  Oligoclonal bands                                        Present             Absent
  B lymfocytes (%)                                         7.80                --
  Plasma cells (%)                                         1.80                --
  RF IgM[^\*^](#TN1){ref-type="table-fn"} (\<15 IU/mL)     92.7                Negative
  Anti-CCP[^\*^](#TN1){ref-type="table-fn"} (\<25 IU/mL)   19,600              64
  CXCL-13 (\<10 ng/L)                                      \>500               \<10

*Range in serum; -, not performed*.

Cerebrospinal Fluid (CSF) analysis revealed a mononuclear pleocytosis (170 E6/L) and elevated protein level (1.16 g/L). Due to the pleocytosis, intravenous ceftriaxone, and aciclovir were administered, to cover for bacterial meningitis and Herpes Simplex Virus (HSV) encephalitis. Subsequent CSF cultures revealed no growth of bacteria, no Borrelia antibodies, and viral/bacterial PCR *(E. coli, hemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, hemolytic streptococcus, streptococcus pneumoniae, cytomegalovirus, enterovirus, herpes simplex virus, varicella zoster, Cryptococcus, and micromiome 16S/18S*), and flowcytometry, and cytological analysis for malignancy were negative. Therefore, antiviral- and antibiotic- treatment was terminated.

The following days the patient displayed sporadic confusion, delusions, and fever (38.5°C). Subsequent tests, including HIV, syphilis, and tuberculosis were negative. Re-examination of CSF showed continuous mononuclear pleocytosis (130 E6/L), high IgG index (1.45) and presence of oligoclonal bands, suggestive of inflammation. Repeated cultures for bacteria were negative and cytological analysis showed an inflammatory pattern with an elevated number of B-lymphocytes (7.8 %) and plasma cells (1.8%, [Table 1](#T1){ref-type="table"}).

To investigate possible systemic inflammation or malignancy whole-body FDG-PET CT was performed. This showed hypermetabolism of the cerebral cortex, adjacent to the meningeal enhancement found on MRI, and a right medial lobe infiltrate of the lung. CT of thorax and abdomen confirmed an infiltrate, slight pleural effusion, and pleural thickening. Endobronchial ultrasound with biopsy was performed revealing no malignancy or infection.

On suspicion of RM, we performed analysis on undiluted CSF showing moderately positive IgM RF (92.7 IU/mL) and strongly positive anti-CCP (19,600 IU/mL) and CXCL-13 (\>500 ng/L, [Table 1](#T1){ref-type="table"}).

Subsequent, biopsy of meninges ([Figure 1C](#F1){ref-type="fig"}) confirmed chronic inflammation dominated by CD138 positive plasma cells and a limited number of CD3 positive T-lymphocytes with limited infiltration into the underlying gray matter ([Figures 1E,F](#F1){ref-type="fig"}). Additionally, granulomatous inflammation with dense infiltration of CD68+ histiocytes and the presence of rheumatoid nodules were found ([Figures 1D,G](#F1){ref-type="fig"}). Microbial stains, PCR, and cultures of biopsy tissue for fungi, parasites, acid-fast bacilli, HSV 1, HSV 2, CMV, SV40, M. tuberculosis, and toxoplasmosis were negative.

Based on the (i) MRI findings with patchy meningeal enhancement, (ii) high titer of IgM-RF and anti-CCP in CSF and (iii) histopathological chronic inflammation of meninges with plasma cells and rheumatic nodules, the diagnosis RM was established. Concurrently, the patient displayed extra articular manifestations of RA in her lungs.

Intravenous high dose methylprednisolone (750 + 1,000 + 1,000 mg on three consecutive days) followed by oral tapering was administered in addition to current treatment with methotrexate. Within days symptoms improved, but did not completely resolve. The following weeks, the patient received Rituximab (1,000 mg intravenous, repeated after 14 days). CSF levels of IgM RF, anti-CCP, and CXCL-13 decreased accordingly to the patient reporting significant treatment response ([Table 1](#T1){ref-type="table"}). A 6 month follow-up MRI showed regression of meningeal enhancement ([Figure 1B](#F1){ref-type="fig"}) and follow-up FDG-PET CT showed almost complete regression of pulmonary findings. Neurological examination at 6 month follow up confirmed resolution of clinical symptoms.

Discussion {#s3}
==========

Meningitis in RA is a rare serious extra-articular complication ([@B1], [@B2], [@B7], [@B16]). Clinical neurological manifestations are often non-specific and duration and manifestations of RA is unreliable, as less than half of patients display active synovitis ([@B2], [@B17]). Sometimes CNS involvement even precedes the onset of arthritis ([@B17]--[@B20]). In cases published since 2010, 34% (13 of 38) had no history of RA before the diagnosis of RM ([Table A1](#TA1){ref-type="table"}). CSF findings are variable but most often include a mild pleocytosis with elevated protein concentration and normal glucose ([Table A1](#TA1){ref-type="table"}). Gadolinium enhanced MRI is often useful, showing asymmetrical pachy- or leptomeningeal enhancement ([@B11], [@B18]). Recently, a review of 29 cases of RM showed definite asymmetric meningeal involvement in 62% of patients, and most common neurological features were hemiparesis or hemisensory symptoms mimicking stroke or epilepsy related to localization of meningeal involvement ([@B11]). In comparison to this, we find that 70% (33 of 47) had transient or permanent weakness, sensory deficits, or speech disorders, whereas 36% (17 of 47) had seizures ([Table A1](#TA1){ref-type="table"}) It is not uncommon that patients display other extra-articular manifestations of RA such as subcutaneous nodules or pulmonary manifestations, as seen in our case ([@B2], [@B5], [@B21], [@B22]).

Patients with RA are often treated with various immunosuppressants which increase the risk of aseptic meningitis or opportunistic infections. Therefore, it is important to rule out iatrogenic aseptic, septic, and fungal diseases before diagnosis of RM. Concurrently, autoimmune diseases, malignancies, other granulomatous diseases or IgG4-related disease can display a similar pattern of dural thickening, making them possible considerations in the differential diagnosis of RM ([@B10], [@B11], [@B16]).

Until now, there are no known RM biomarkers in CSF and meningeal biopsy is required for definite diagnosis. Biopsy shows thickening of meninges ([Figure 1C](#F1){ref-type="fig"}) and histopathological features include pachy- and leptomeningeal inflammation with plasma cells and the presence of rheumatoid noduli, and in some cases vasculitis ([@B1], [@B2], [@B17]). Patients diagnosed at autopsy almost all display meningeal rheumatoid noduli, while patients diagnosed with meningeal biopsy most often show non-specific inflammation ([@B2], [@B7]). In some previous cases correlation between strongly elevated CSF RF and Il-6 and RM has been proposed ([@B12], [@B13], [@B23], [@B24]), however this still needs validation as a diagnostic tool.

No clear guideline for treatment of RM exists and cyclophosphamide, methotrexate, and azathioprine in combination with corticosteroids have all been described with improvement of symptoms ([@B7], [@B17], [@B18], [@B25]). In some cases, improvement on corticosteroid treatment alone has been described ([@B5], [@B11], [@B12], [@B14], [@B20], [@B24], [@B26]--[@B31]). In our case review 41% (18 of 44) were treated with corticosteroids alone, 2% (1 of 44) received no treatment, whereas the remaining received corticosteroids in combination with another therapy ([Table A1](#TA1){ref-type="table"}). Seven patients (16 %) received rituximab. On these regimens only 1 case worsened ([@B32]), 8 (18%) had an incomplete improvement, whereas 80% improved ([Table A1](#TA1){ref-type="table"}).

To our knowledge, anti-CCP in CSF has only been examined in four cases of RM and found to be elevated in three of these ([@B12]--[@B15]). Serum anti-CCP antibodies help distinguish RA from other types of arthritis, can help to identify patients with a higher risk of severe disease and are rarely found in other autoimmune conditions ([@B33]). They are often used in combination with IgM RF in the diagnosis of RA. In this case, anti-CCP level in CSF was strongly positive and a crucial element in both diagnosing RM and monitoring treatment response. With this case, we show a novel clear response of anti-CCP to the treatment of RM. Moreover, in addition to CSF anti-CCP and IgM RF, we also find the B cell chemoattractant CXCL-13 levels associated with treatment response, which to our knowledge has not previously been investigated.

We propose using anti-CCP, IgM RF, and CXCL-13 in CSF as potential biomarkers not only for diagnosis of RM, but also in evaluation of treatment response. Further studies are needed to clarify their potential use.
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###### 

Summary of RM cases from 2010 to present.

  **References**                 **Patient (Age, sex)**   **Years of RA**   **Treatment of RA**                          **Symptoms of RM**                                                                    **Serum**     **CSF**             **MRI compatible with RM**                                **Biopsi compatible with RM**   **Treatment**    **Outcome**                                                                                                                                                                                             
  ------------------------------ ------------------------ ----------------- -------------------------------------------- ------------------------------------------------------------------------------------- ------------- ------------------- --------------------------------------------------------- ------------------------------- ---------------- ----------------- --------------------------- ------------------- ------------------------ ----------------------- ------------------------------------ ----------------------------------------------- ------------------------
  Cianfoni et al. ([@B32])       74, F                    5                 CS, MTX                                      Progressive left-side weakness and hypoesthesia                                       506           --                  --                                                        65                              0.43             Normal            --                          --                  --                       Yes                     Yes                                  CS, IT MTX                                      Worsening
  Matsushima et al. ([@B24])     80, F                    20                CS, sulfasalazine, bucillamine, etanercept   Transient weakness and numbness right-side                                            Normal        --                  --                                                        18                              0.55             --                --                          --                  IL-6 = 4.6 pg/ml         Yes                     Yes                                  CS                                              Improvement
  Inan et al. ([@B34])           70, F                    0                 None                                         Headache, nausea, vomiting, and confusion                                             108           --                  ESR = 124 mm/h                                            140                             1.13             34                98 (after treatment \<20)   --                  --                       Normal                  Not performed                        CS, AZA                                         Improvement
  Aguilar-Amat et al. ([@B35])   71, F                    15                NR                                           Seizures and PSP-like phenotype                                                       27.9          --                  --                                                        Normal                          Normal           Normal            --                          --                  --                       Yes                     Yes                                  CS, MTX                                         Improvement
  Kim et al. ([@B26])            66, M                    0                 None                                         Seizures (SE) and left-sided weakness                                                 High levels   1,448               ANA high                                                  11                              Normal           Normal            --                          --                  --                       Yes                     Yes                                  CS                                              Improvement
  Servioli et al. ([@B36])       80, F                    NR                CS, HCQ                                      Unsteady gait with falls. Progression to left-sided weakness                          \<20          --                  ESR = 35 mm/h                                             2--7                            0.75--0.77       60                --                          --                  --                       Yes                     Yes                                  Not reported                                    Not reported
  Hasiloglu et al. ([@B37])      62, F                    4                 CS, MTX                                      Headache, paresis, and paresthesia right UE                                           351           120                 --                                                        40                              0.40             --                --                          --                  --                       Yes                     Not performed                        CS, MTX                                         Improvement
  Huys et al. ([@B38])           58, F                    9 month           MTX, Adalimumab                              Headache and psychomotor retardation, seizures                                        --            --                  --                                                        30                              0.55             --                --                          --                  --                       Yes                     Yes                                  CS, RTX, Leflunomide, MTX d/c, Adalimumab d/c   Improvement
  Duray et al. ([@B22])          73, M                    1                 CS, MTX                                      Disorientation, apathy, and astenia, walking difficulty                               2,720         \>340               --                                                        83--91                          1.3--2.22        42--58            --                          --                  --                       First MRI normal, yes   Yes                                  CS, CYC                                         Improvement
  Krysl et al. ([@B5])           62, M                    10                HCQ                                          Epilepsia partialis continua right side                                               1:320         760                 --                                                        0--32                           0.245--0.345     --                --                          --                  OCBs in one CSF sample   Yes                     Yes (2 year after initial symtoms)   CS                                              Improvement
  Roques et al. ([@B39])         60, M                    NR                MTX                                          Transient right-sided paresis and hypoesthesia                                        --            --                  --                                                        Increased                       Mild elevation   Normal            --                          --                  --                       Yes                     Yes                                  Not reported                                    Not reported
  Hayashi et al. ([@B4])         60, M                    10                CS                                           Parkinsonism not responsive to levo-dopa                                              --            --                  --                                                        13                              0.75             Normal            --                          --                  --                       Yes                     Yes                                  CS                                              Incomplete improvement
  Bourgeois et al. ([@B40])      70, M                    NR                NR                                           Transient right hemiparesis, headache                                                 Positive      --                  --                                                        68                              0.47             2,9 mmol /L       --                          --                  --                       Yes                     Yes                                  CS, HCQ, sulfasalazine                          Improvement
  Rijkers et al. ([@B6])         57, F                    NR                NR                                           Tonic-clonic seizures                                                                 --            --                  --                                                        --                              --               --                --                          --                  --                       Yes                     Yes                                  CS                                              Not reported
  Yeaney et al. ([@B9])          63, M                    9                 NR                                           Headache and paresis                                                                  --            --                  --                                                        --                              --               --                --                          --                  --                       Yes                     Yes                                  Not reported                                    Not reported
  Padjen et al. ([@B20])         77, F                    0                 None                                         Seizures and right hemiparesis                                                        171.7         405.3               --                                                        Normal                          Normal           Normal            --                          --                  --                       Yes                     Yes                                  CS                                              Improvement
  Lu et al. ([@B27])             60, F                    23                CS, Auranofin                                Headache, photophobia, insomnia, panic attacks, hallucinations                        \>1:160       Strongly positive   --                                                        2                               0.26             58                --                          --                  --                       Yes                     Yes                                  CS                                              Improvement
  Roy et al. ([@B3])             Late 50s, F              NR                MTX, sulfasalazine                           Transient aphasia, confusion, headache right leg weakness, right facial drop          --            High                --                                                        12                              0.55             58                --                          --                  --                       Yes                     Yes                                  MTX, MMF, MTX d/c                               Improvement
  Magaki et al. ([@B28])         37, M                    0                 None                                         Headache, facial weakness, speech disorder, right hand dysfunction                    83            \>250               --                                                        10--16                          0.35--0.50       50--89            --                          --                  --                       Yes                     Yes                                  CS                                              Improvement
  Magaki et al. ([@B28])         62, F                    0                 None                                         Confusion and transient loss of consiousness, seizures, and lower limb weakness       Negative      --                  --                                                        --                              --               --                --                          --                  --                       Not reported            Yes                                  CS                                              Incomplete improvement
  Nihat et al. ([@B41])          71, F                    6                 Adalimumab, MTX                              Dysarthria, paresthesia left face and arm, difficulty walking, tremor, and headache   7,900 U/L     226                 ESR = 76 mm/h; ANA 1:80                                   50--80                          0.46--0.67       2.4 mmol/L        --                          --                  --                       Yes                     Yes                                  CS, CYC, MTX                                    Improvement
  Saego et al. ([@B29])          66, F                    12                Infliximab                                   LE numbness, aphasia developing into headache, LE paralysis                           --            --                  --                                                        213--216                        4.4--8.59        41--44            RF elevated                 --                  --                       Yes                     Yes                                  CS                                              Improvement
  Shibahara et al. ([@B12])      63, M                    0                                                              Headache, vertigo, confusion                                                          140           472                 ESR = 18 mm/h                                             37                              0.92             Normal            --                          4.4--26.2           IL-6 = 482 pg/ml         Yes                     Not performed                        CS                                              Improvement
  Matsuda et al. ([@B21])        66, M                    19                CS, MTX, iguratimod                          Falls                                                                                 160           310                 ESR = 38 mm/h; ANA 1:5120; SSA and SSB positive           71                              1.14             27                                            --                  --                       Yes                     Not performed                        CS, MTX d/c                                     improvement
  Moeyersoons et al. ([@B42])    49, F                    N/A               N/A                                          N/A                                                                                   N/A           N/A                 N/A                                                       N/A                             N/A              N/A               N/A                         N/A                 N/A                      N/A                     Not performed                        CS, RTX. adalimumab d/c, leflunomide d/c        Improvement
  Tsuzaki et al. ([@B43])        65, M                    7 month           CS, MTX, Entanercept                         Transient loss of consciousness, seizures, transient dysrthria, left leg weakness     12            275                 sIL2R = 555 U/mL; ANA = 80; SSA 297 U/mL; SSB 18.6 U/mL   12                              0.32             55                                            --                  --                       First normal, yes       Yes                                  CS, tocilizumab, etanercpt d/c                  Improvement
  Choi et al. ([@B11])           65, F                    3                 CS, MTX, leflunomide                         Headache, confusion, and recurrent left hemiparesis                                   69.3          48.8                --                                                        20                              1.134            43                RF 17.6                     --                  --                       Yes                     Yes                                  CS                                              Improvement
  Degboé et al. ([@B44])         59, M                    6                 MTX                                          Transient right-sided hypoesthesia and hemiparesis                                    --            --                  --                                                        30                              0.75             3.2 mmol/L        --                          --                  --                       Yes                     Yes                                  CS, MTX, RTX                                    Improvement
  Jessee and Keenan([@B45])      68, F                    0                 None                                         Confusion, right-sided weakness, and seizures                                         208           95.8                ANA 1:640                                                 8                               0.65             56                --                          --                                           Not done (pacemaker)    Yes                                  CS, MTX                                         Incomplete improvement
  Alexander et al. ([@B46])      73, M                    NR                Leflunomide                                  Transient speech disorder, behavoiral change and seizure                              45            \>340               --                                                        18--100                         0.69--1.03       2.5--3.1 mmol/L   --                          --                                           Yes                     Yes                                  CS, RTX                                         Incomplete improvement
  Finkelshtein et al. ([@B19])   66, F                    0                 None                                         Headache, transient paresthesia left leg                                              23--25        266                 --                                                        --                              --               --                --                          --                  --                       Yes                     Yes                                  None                                            Improvement
  Parsons et al. ([@B47])        76, M                    30                MTX                                          Transient left UE paresis, new onset seizures                                         Elevated      Elevated            ANA elevated                                              239                             0.39             51                RF negative                 --                  --                       Yes                     Yes                                  CS, MTX                                         Improvement
  Oono et al. ([@B23])           36, F                    13                CS, MTX                                      Headache and transient sensory disturbance right face and UE                          --            --                  ESR = 56 mm/h; anti-RNP = 15 U/mL                         19                              0.57             51                                            --                  IL−6 = 843 pg/ml, OCBs   Yes                     Not performed                        CS, MTX d/c                                     Improvement
  Akamatsu et al. ([@B13])       55, F                    6 month           MTX                                          Speech difficulty, left-sided hemiparesis, and spatial neglect                        85 U/L        223.7                                                                         68                              0.40             52                                            3.7                 IL-6 = 271 pg/mL         Yes                     Not performed                        CS                                              Incomplete improvement
  Gherghel et al. ([@B10])       77, F                    \>9 year          Ethanercept, leflunomide                     Recurrent speech disorder and left-sided paresthesia and hemparesis                   86            119                 ANA 1:160                                                 5                               0.49             --                --                          --                  --                       Yes                     Yes                                  CS, etanercept d/c, leflunomide d/c             Incomplete improvement
  Schuster et al. ([@B14])       48, M                    0                 None                                         Headache, recurrent left-sided weakness                                               298           \>340               --                                                        300                             1.37             --                --                          \>340               --                       Yes                     Not performed                        CS                                              Improvement
  Schuster et al. ([@B14])       62, F                    Not stated        NR                                           Recurrent tingling and weakness                                                       146           265                 --                                                        Normal                                           --                --                          --                  --                       Yes                     Not performed                        CS, MTX                                         Improvement
  Schuster et al. ([@B14])       72, M                    0                 None                                         Recurrent sensory motor deficit left-side                                             133           154                 --                                                        51                              Normal           --                --                          --                  --                       Yes                     Yes                                  CS                                              Improvement
  Schuster et al. ([@B14])       62, M                    11                NR                                           Alexia, agraphia, acalculia, headache, seizures                                       22.3          329                 --                                                        Normal                          Normal           --                --                          --                  --                       Yes                     Not performed                        CS, tocilizumab                                 Improvement
  Schuster et al. ([@B14])       65, F                    11                NR                                           Recurrent sensory motor deficit left-side, speech disorder                            313           26                  --                                                        8                               0.653            --                --                          --                  --                       Yes                     Yes                                  CS, tocilizumab, leflunomide d/c; MTX d/c       Improvement
  Schuster et al. ([@B14])       45, M                    30                NR                                           Recurrent left-side hypoesthesia, headache, ataxia                                    113           7                   --                                                        37                              4.6              --                --                          --                  --                       Yes                     Yes                                  CS, CYC, MTX, leflunomide d/c; HCQ d/c          Improvement
  Ching et al. ([@B31])          72, F                    0                 None                                         Left-sided weakness, psychiatric symptoms, seizures                                   Negative      197.5               ESR = 39 mm/h                                             12                              0.25             58                --                          --                  --                       Yes                     Yes                                  CS                                              Improvement
  Harrison et al. ([@B48])       53, M                    NR                CS, leflunomide, tofacitinib citrate         Headache, seizures, right LE paresis                                                  293           250                 ESR 46 mm/h                                               7                               0.64             48                --                          --                  --                       Yes                     Yes                                  CS, RTX                                         Improvement
  McKenna et al. ([@B30])        59, M                    0                 None                                         Headache and left-sided weakness, focal onset seizures                                88.2          \>340               ACE = 70 U/L                                              Pleocytosis                     0.672            3.4 mmol/L        --                          --                  --                       Yes                     Yes                                  CS                                              Improvement
  Pellerin et al. ([@B1])        74, M                    3--4              CS, HCQ, MTX                                 Expressive aphasia, imbalance, potural tremor, parkinsonism, seizures                 High          High                ACE 66 U/L, beta 2 mikroglobulin 4,6 mg/L                 6                               0.86             Normal            --                          --                  --                       Yes                     Yes                                  CS, CYC, MTX d/c                                Incomplete improvement
  Grose et al. ([@B49])          87, F                    NR                None                                         UE weakness, confusion, hallucinations                                                143           \>200               ANA 1:640                                                 104                             1.55             Normal            --                          --                  --                       Yes                     Not performed                        CS                                              Incomplete improvement
  Scheitel et al. ([@B50])       75, F                    9                 CS, leflunomide                              UE paresthesia, weakness, headache, facial jerks, Rytmic jerks                        High          High                ESR = 92 mm/h                                             14                              0.69             --                --                          --                  --                       Yes                     Not performed                        CS, RTX                                         Improvement
  Lubomski et al. ([@B15])       49, M                    0                 None                                         Headache, deterioration in mental state, delusions                                    8             \>600               --                                                        1                               0.39             3.4 mmol/l                                    Strongly positive                            Yes                     Yes                                  CS, RTX                                         Improvement

*ACE, angiotensin converting enzyme; ANA, antinuclear antibodies; AZA, azathioprin; CS, corticosteroids; CYC, cyclophosphamide; d/c, discontinued; ESR, erythrocyte sedimentation rate; F, female; HCQ, Hydroxychloroquine; IL-6, interleukin-6; IT, intrathecal; LE, lower extremity; M, male; MTX, methotrexate; MMF, Mycophenolate mofetil; N/A, not avaliable; NR, not reported; RA, rheumatoid arthritis; RF, rheumatic factor; RM, rheumatoid meningitis; RNP, ribonucleoprotein; RTX, Rituximab; sIL2R, soluble interleukin-2 receptor; SSA, Anti-Sjögren\'s-syndrome-related antigen A; SSB, Sjögren\'s-syndrome-related antigen B; UE, upper extremity*.
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